DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon

Etude observationnelle des patients traités par natalizumab pour une sclérose en plaques, en situation réelle de prescription, en région Centre

TOURS-BU Médecine (372612103) / SudocSudocFranceF

Utilisation de la mitoxantrone (Mx) dans la sclérose en plaques (expérience tourangelle)

TOURS-BU Médecine (372612103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Effets au long cours de l'administration in vivo d'un anticorps anti-VLA4 (natalizumab) sur la mobilisation des progéniteurs hématopoïétiques primitifs et différenciés chez l'homme

TOURS-BU Sciences Pharmacie (372612104) / SudocSudocFranceF

Pratique d’une activité physique de loisir chez les patients atteints de sclérose en plaques en région Centre-Val de Loire

International audienc

Pregnancy and birth outcomes in MS women : comparison of the RESPONSE cohort to the general French population

International audienc

Long-Term Effects of In Vivo Administration of An Anti-VLA-4 Antibody (natalizumab) on Mobilization of Committed and Primitive Hematopoietic Progenitor Cells In Humans.

International audienc

The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics

International audienceBackground: Counseling on pregnancy is still challenging, particularly regarding the use of disease-modifying treatments (DMTs). We are lacking long-term outcomes in children exposed to DMTs.Objectives: This study aimed to set up a French pregnancy registry for women with multiple sclerosis (MS) and related disorders nested within the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort.Methods: Prospective, observational, multicentric, epidemiological study in France. Neurological visits are organized according to routine practice. Data are collected on the OFSEP minimal datasheet. Auto-questionnaires on pregnancy are completed by patients at Months 5-6 and 8 during pregnancy, and Months 3, 6, and 12 postpartum. A specific survey on analgesia is completed by anesthesiologists. Pediatric data are collected from the child's health book, where visits on Day 8, Month 9, and 24 are mandatory. Parents complete neurodevelopmental questionnaires at Year 1, Years 2 and 6.Results: The RESPONSE study started in August 2019. On 7 April 2023, 515 women were included. Baseline demographics are presented.Conclusions: RESPONSE will provide rich information on the global management of pregnancy in France and prospective data on children until the age of 6 years, exposed or not to a DMT, including data on neurodevelopment that can be compared to the general population.Study funding: EDMUS and ARSEP Foundation, Biogen, Roche

Congenital Trypanosomiasis in Child Born in France to African Mother

International audienc